colitis and glp-1 GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk Weight Loss Medications & IBD

Novo Nordisks Response to the Lawsuits Novo Nordisks Response to the Lawsuits In the face of mounting legal challenges regarding Ozempic, Novo Nordisk has adopted a multi-faceted approach to address the concerns and defend its product: Official Statements and Public Defense: Novo Nordisk has consistently maintained that patient safety is its highest priority

But what we do hate is when they arent transparent and honest about these price increases

The non-metabolizable glucose analog and SGLT-1 agonist, -methylglucopyranoside, is also a potent stimulator of GLP-1 release from primary intestinal L-cell cultures, highlighting this transporter as a major stimulator of hormone release from EECs (27)

While these agents were initially developed for glycemic control, their impact extends beyond glucose regulation